Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
61.4M
-
Number of holders
-
131
-
Total 13F shares, excl. options
-
53.4M
-
Shares change
-
+2.72M
-
Total reported value, excl. options
-
$422M
-
Value change
-
-$73.7M
-
Put/Call ratio
-
0.19
-
Number of buys
-
67
-
Number of sells
-
-70
-
Price
-
$7.91
Significant Holders of Protagonist Therapeutics, Inc - Common Stock (PTGX) as of Q2 2022
177 filings reported holding PTGX - Protagonist Therapeutics, Inc - Common Stock as of Q2 2022.
Protagonist Therapeutics, Inc - Common Stock (PTGX) has 131 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 53.4M shares
of 61.4M outstanding shares and own 86.93% of the company stock.
Largest 10 shareholders include STATE STREET CORP (6.78M shares), RTW INVESTMENTS, LP (4.79M shares), Point72 Asset Management, L.P. (4.06M shares), FARALLON CAPITAL MANAGEMENT LLC (3.7M shares), FMR LLC (3.49M shares), BlackRock Inc. (3.45M shares), VANGUARD GROUP INC (2.73M shares), JOHNSON & JOHNSON (2.45M shares), Bain Capital Life Sciences Investors, LLC (2.26M shares), and MORGAN STANLEY (1.78M shares).
This table shows the top 131 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.